Aditxt Inc (ADTX) Stock Price, Quote & News

Company Profile

Aditxt, Inc., a commercial-stage company, discovers and develops products in the areas of immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore that enable individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 870 1200

Website: www.aditxt.com

Address:

2569 Wyandotte Street, Suite 101, Mountain View, United States

Bigwinner75 Dec. 14 at 2:14 AM

$ADTX bottom line, if company dillute that 200 million from 2 dollars, you wil not be compliance by next May, shorts will be over, buyer has no interested, if you dillute at 3-5 dollars, maybe you can barelt be above 1 dollar by May, so pull the stock up to 8 dollars is the best, you have no reverse split left until next circle, you can vote, but you are not allowed to do , 8 dollar or OTC

1 · Reply

Bigwinner75 Dec. 14 at 12:34 AM

$ADTX if i were the company, i would be very careful dillute now, 200 million can send this under one dollar quickly, panic, low sentiment, haters in social media, 10 cent is very likely reachable, and if so, will never reach 1 dollar again, so you will not be compliance by next may 2026, no reverse split alowed, delisting is the only way to go, that is bad for all or us, so please make a statement says temp hault dullute, please, you dont want to be the second $MULN

0 · Reply

Bigwinner75 Dec. 14 at 12:23 AM

$ADTX the last thing company want is a hater like me cry about lost all his money on social media, and can not reach the compliance and can not go to another reversen split, they have used all these slot, the earliest time for reverse split is next May, 2026, and 200 million will crush this, so hold off your emo, pump this thing is our best option

0 · Reply

Bigwinner75 Dec. 13 at 11:46 PM

$ADTX if you dillute now, you will end up with 200 million shares or 300, 400, 500 million shares , people lost interest, you might have to dump to 10 cents for some discord people to come for a pump, then you will be facing another 100 to 1 reverse split , i garanttee you nasdaq will deny you , and send to OTC so you can be in bed with $EVFM

0 · Reply

Bigwinner75 Dec. 13 at 11:41 PM

$ADTX stock just went thru a huge reverse split, people are scared, it has been a dilute machine, nasdaq is elimate all kinds of diluting stock, panel are gettiing more strict, you can dump the 200 mil, send this to OTC, or you wait, find a better price and sentiment to sell

0 · Reply

Bigwinner75 Dec. 13 at 11:35 PM

$ADTX once their next reverse split request is denied, they can go to OTC to be with their ex husband $EVFM , no volume, no buyer, and no more offering, so company needs to come up a plan , negociate with us

0 · Reply

Bigwinner75 Dec. 13 at 11:33 PM

$ADTX company cannot do unlimited reverse splits inside the same compliance period. they just did one, and it was a big one 113 to 1, and two month later they fell under one dollar, nasdaq will review its reverse request , and say no, that is our only card, to stop them from selling 200 milion imediatley because it will send this straight under one dollars, breaks confidence, people lost interest

0 · Reply

Bigwinner75 Dec. 13 at 11:29 PM

$ADTX we need a brain, not just courage, we run out of cards

0 · Reply

Bigwinner75 Dec. 13 at 11:27 PM

$ADTX now they pull out a weapon, and they are in favor

0 · Reply

Bigwinner75 Dec. 13 at 11:24 PM

$ADTX they scared, you dont want this thing fly 100 times to blow up thier short account, so we need to work a deal with them

0 · Reply

Aditxt Provides Updates on its Growth Vision for bitXbio™, Planned Digital Asset Treasury, Pearsanta's Planned IPO, And Evofem's Plan to Regain a National Listing

Oct 29, 2025, 4:30 PM EDT - 6 weeks ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-113 Reverse Stock Split Effective at the Open of Trading on November 3, 2025

Oct 27, 2025, 8:30 AM EDT - 6 weeks ago

Aditxt Subsidiary Pearsanta Begins Enrollment in First Human Study of Blood-Based Diagnostic for Endometriosis, a Condition Affecting 190 Million Women Worldwide and Representing a $1.45 Billion Global Market

Oct 20, 2025, 4:19 PM EDT - 7 weeks ago

Evofem Announces Voting Results from Special Meeting of Stockholders

Sep 11, 2025, 9:18 AM EDT - 3 months ago

Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms

Sep 9, 2025, 9:28 AM EDT - 3 months ago

Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

Aug 25, 2025, 9:15 AM EDT - 3 months ago

Aditxt's Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at Over $160 Billion by 2030

Aug 21, 2025, 8:56 AM EDT - 4 months ago

Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

Aug 19, 2025, 9:39 AM EDT - 4 months ago

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

Aug 14, 2025, 8:46 AM EDT - 4 months ago

Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

Aug 11, 2025, 8:30 AM EDT - 4 months ago

Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Aug 5, 2025, 8:46 AM EDT - 4 months ago

Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference

Jul 29, 2025, 9:00 AM EDT - 4 months ago

Aditxt's Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases

Jul 24, 2025, 8:15 AM EDT - 5 months ago

Aditxt's Subsidiary Pearsanta Receives an Invitation to Submit Full Proposal for the U.S. Department of Defense Pilot Award for the Development of its Mitomic® Ovarian Test

Jul 22, 2025, 8:15 AM EDT - 5 months ago

Aditxt to Present at Wall Street Reporter's Next Super Stock Livestream Today July 22, 2025, at 1 p.m. ET

Jul 15, 2025, 9:12 AM EDT - 5 months ago

Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy

Jul 7, 2025, 8:15 AM EDT - 5 months ago

Aditxt Unveils bitXbio™: A Bitcoin-Backed Treasury Strategy Designed to Accelerate Biotech Commercialization

Jun 26, 2025, 8:15 AM EDT - 6 months ago

Aditxt to Present at Wall Street Reporter's NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET

Jun 11, 2025, 8:14 AM EDT - 6 months ago

Notable Data on Evofem's SOLOSEC in Recurrent Bacterial Vaginosis (BV) Released at ACOG Annual Meeting

Jun 9, 2025, 8:15 AM EDT - 6 months ago

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Jun 5, 2025, 8:15 AM EDT - 6 months ago

Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6

May 19, 2025, 8:00 AM EDT - 7 months ago

Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics

May 2, 2025, 9:00 AM EDT - 8 months ago

Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™

Apr 17, 2025, 8:15 AM EDT - 8 months ago

Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

Apr 16, 2025, 8:15 AM EDT - 8 months ago

Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025

Apr 14, 2025, 8:15 AM EDT - 8 months ago

Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

Apr 11, 2025, 8:15 AM EDT - 8 months ago

Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements

Apr 9, 2025, 8:15 AM EDT - 8 months ago

Aditxt, Inc. (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

Apr 2, 2025, 8:15 AM EDT - 9 months ago

Appili President and CEO, Don Cilla Will Join Aditxt Co-founder and CEO, Amro Albanna, at the Aditxt Weekly Update on April 4, 2025

Mar 28, 2025, 8:15 AM EDT - 9 months ago

Upcoming Aditxt Weekly Update to Highlight Pearsanta's Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer Detection

Mar 24, 2025, 8:30 AM EDT - 9 months ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

Mar 24, 2025, 8:15 AM EDT - 9 months ago

Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk

Mar 17, 2025, 8:15 AM EDT - 9 months ago

Aditxt Provides Business Status Overview and Announces Launch of Aditxt Weekly Update Starting Friday, March 21, 2025

Mar 12, 2025, 4:15 PM EDT - 9 months ago

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-250 Reverse Stock Split Effective at the Open of Trading on March 17, 2025

Mar 6, 2025, 8:15 AM EST - 10 months ago

Aditxt Subsidiary Adimune to Ship Drug Substances for Final Drug Product Formulation of ADI-100 Ahead of Planned Clinical Trials in Type 1 Diabetes and Psoriasis in Germany, and Stiff Person Syndrome at the Mayo Clinic in the U.S.

Feb 21, 2025, 8:15 AM EST - 10 months ago

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Feb 13, 2025, 8:15 AM EST - 10 months ago

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Jan 13, 2025, 8:15 AM EST - 11 months ago

Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Dec 12, 2024, 8:15 AM EST - 1 year ago

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Nov 14, 2024, 4:36 PM EST - 1 year ago

Evofem Biosciences Announces Financial Results for the Third Quarter of 2024

Nov 8, 2024, 8:30 AM EST - 1 year ago

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Nov 7, 2024, 8:30 AM EST - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Nov 6, 2024, 8:30 AM EST - 1 year ago

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Nov 6, 2024, 8:00 AM EST - 1 year ago

Evofem Secures Investor Support for Proposed Merger through Voting Agreements

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Aditxt's Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Oct 30, 2024, 5:00 PM EDT - 1 year ago

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Oct 29, 2024, 8:15 AM EDT - 1 year ago

Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

Oct 28, 2024, 8:15 AM EDT - 1 year ago

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Oct 21, 2024, 8:15 AM EDT - 1 year ago

Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time

Oct 10, 2024, 8:15 AM EDT - 1 year ago

Aditxt's Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili's Shareholder Approval

Bigwinner75 Dec. 14 at 2:14 AM

1 · Reply

Bigwinner75 Dec. 14 at 12:34 AM

0 · Reply

Bigwinner75 Dec. 14 at 12:23 AM

0 · Reply

Bigwinner75 Dec. 13 at 11:46 PM

0 · Reply

Bigwinner75 Dec. 13 at 11:41 PM

0 · Reply

Bigwinner75 Dec. 13 at 11:35 PM

0 · Reply

Bigwinner75 Dec. 13 at 11:33 PM

0 · Reply

Bigwinner75 Dec. 13 at 11:29 PM

$ADTX we need a brain, not just courage, we run out of cards

0 · Reply

Bigwinner75 Dec. 13 at 11:27 PM

$ADTX now they pull out a weapon, and they are in favor

0 · Reply

Bigwinner75 Dec. 13 at 11:24 PM

$ADTX they scared, you dont want this thing fly 100 times to blow up thier short account, so we need to work a deal with them

0 · Reply

Bigwinner75 Dec. 13 at 11:22 PM

$ADTX this asian man is tryin to get out all out, i am down 40%

0 · Reply

THREEFINGER Dec. 13 at 10:07 PM

$ADTX or he’s a paid bear that’s facts just look at his account It’s all fear talk

1 · Reply

THREEFINGER Dec. 13 at 10:05 PM

$ADTX bro this Asian man was bullish just days ago. He ain’t one of us Don’t pay him any attention

1 · Reply

Bigwinner75 Dec. 13 at 9:32 PM

$ADTX maybe deep down I had fear of losing my whole investment, maybe I was using false accusations to send a message to the company manage team to pause the dilution til Q1 2026. Wait for a better price and sentiment

0 · Reply

Bigwinner75 Dec. 13 at 9:29 PM

$ADTX once again I apologize that I accuse you as a paid pumper without any evidence. I have been seen you bullish post here for months now, After reverse split now toxic dillution, and you still used word : ‘ hold’ or ‘ buy more’. It raise a red flag

0 · Reply

Bigwinner75 Dec. 13 at 8:26 PM

$ADTX with stock price at 2 dollars, and sentiment of this reverse split seller stock. With 200 million selling pressure can easily drive the price to 50 cents. And then they will do another reverse split. We could lose all our money What can we do any phd professional advice or we just wait to be slaughtered

1 · Reply

Bigwinner75 Dec. 13 at 8:22 PM

$ADTX worst part is after they secretly sold 175 million dollars on us , yesterday they did a reset to 200 million again without shareholder approval. They use a dark weapon on us. Invisible slaughter machine

0 · Reply

Bigwinner75 Dec. 13 at 8:19 PM

$ADTX the recent small float pump was a scam. There were secret dumping reverse shell shares on us. No matter how much we buy. Price not moving. This is call ATM dilute. It is very disguised. It doesn’t show on the stock float unless they update.

0 · Reply

Bigwinner75 Dec. 13 at 8:00 PM

$ADTX ceo is having getting paid million and luxury vacation with our money , while has no business to run. They think we are his ATM machine. Push a number , and money will come out. And the worst. He starve us to death No pay no reward. Only torture

0 · Reply

Bigwinner75 Dec. 13 at 7:56 PM

$ADTX stock price went though reverse split many time. Just cashed 200 million. Now reset to 200 million.

0 · Reply

Bigwinner75 Dec. 13 at 7:55 PM

$ADTX I will write to Nasdaq next week.

0 · Reply

Bigwinner75 Dec. 13 at 7:54 PM

$ADTX pause atm dilution stable price Or you can send this to 20 cent delist.

0 · Reply

Market Cap	1.64M
Revenue (ttm)	130,000.00
Net Income (ttm)	-34.45M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-26,500.00%
Debt to Equity Ratio	0.00

Volume	207,700
Avg Vol	895,423
Day's Range	N/A - N/A
Shares Out	731,000.00
Stochastic %K	6%
Beta	1.43
Analysts	Strong Buy
Price Target	$61.00